Wang W, Wang Q, Wan D, Sun Y, Wang L, Chen H, et al
Bottom Line Retatrutide Phase 3 results validate a fundamental shift in peptide pharmacology: triple-action mechanisms outperform dual-action in nearly every metabolic parameter
In CagriSema trials, the proportion reaching this threshold was lower approximately 24% in REIMAGINE 2 (which included type 2 diabetes patients) and an estimated 35-40% in REDEFINE 1
[5] This rapid breakdown explains why therapeutic GLP-1 receptor agonists have been chemically modified to resist DPP-4 degradation, thereby extending their duration of action and clinical efficacy in managing diabetes and obesity
g , Current responses at a holding potential of 70 mV elicited by NMDA bath application in GLP-1 receptor-positive neurons of the arcuate nucleus (ARC) with bath application of 50 M GLP-1MK-801, 50 M GLP-1, 50 M MK-801 or artificial cerebrospinal fluid (aCSF)